Imatinib Mesylate Tablet
Product Images NDC 72819-185

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 72819-185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Archis Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib Mesylate Tablets 400 mg Bottle Label (Image 1)

This is a description for a medicine, but the name of the medicine is not mentioned. The usual dosage information is not available and it is made in China. It is a 400mg tablet that needs to be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°Fto 86°F). It is necessary to protect it from moisture and dispense it in a tight container. This medicine is distributed by Archis Pharma LLC and contains 30 tablets. The SIN and GTIN numbers are provided. This drug is only available with a prescription and should be kept out of the reach of children. The expiration date is MM/YYYY.*

FDA Label Image

Imatinib Mesylate Tablets 100 mg Bottle Label (Image 2)

Imatinib Mesylate is a prescription medication available as tablets of 100 mg. The usual dosage information can be found on the prescribing information label. It is recommended to store it at a room temperature of 20°C to 25°C and protect from moisture. The medication should be kept in a tightly closed container, out of reach of children. The drug is distributed by Archis Pharma LLC and the manufacturing location is in China. The lot number and expiration date are also provided.*

FDA Label Image

Imatinib Structural Formula (Image 3)

FDA Label Image

Figure 1 Progression Free Survival (itt Principle) (Image 4)

This appears to be a table or graph related to a study or clinical trial involving two treatments (Fil + Ara-C arm and another arm not labeled), and the percentage of participants who did not experience progression of some condition as well as those who were censored at discontinuation and follow-up. There is also information on the hazard ratio and log-rank test. However, without additional context or information it is difficult to provide a more detailed description.*

FDA Label Image

Figure 2 Time To Progression To Ap Or Bc (itt Principle) (Image 5)

This appears to be a statistical report related to a medical study involving patients taking Imatnib Mesylate and FNeAra-C medications. It seems to indicate that out of 1007 patients, 358 experienced progression to AP or BC, while the rest were censored at discontinuation or follow-up. The report includes hazard ratios and log-rank tests, but without additional context or information it is difficult to understand the full meaning or implications of these findings.*

FDA Label Image

Figure 3: Study 1 Recurrence-free Survival (itt Population) (Image 6)

FDA Label Image

Figure 4: Study 2 Recurrence-free Survival (itt Population) (Image 7)

FDA Label Image

Figure 5: Study 2 Overall Survival (itt Population) (Image 8)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.